ATE78169T1 - Behandlung von diabetes durch kombinierte insulinformen. - Google Patents
Behandlung von diabetes durch kombinierte insulinformen.Info
- Publication number
- ATE78169T1 ATE78169T1 AT88904864T AT88904864T ATE78169T1 AT E78169 T1 ATE78169 T1 AT E78169T1 AT 88904864 T AT88904864 T AT 88904864T AT 88904864 T AT88904864 T AT 88904864T AT E78169 T1 ATE78169 T1 AT E78169T1
- Authority
- AT
- Austria
- Prior art keywords
- insulin
- function
- liver
- targeted
- encapsulated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/143,180 US4863896A (en) | 1984-05-03 | 1988-01-13 | Diabetic control by combined insulin forms |
EP88904864A EP0358709B1 (de) | 1988-01-13 | 1988-05-13 | Behandlung von diabetes durch kombinierte insulinformen |
PCT/US1988/001536 WO1989006540A1 (en) | 1988-01-13 | 1988-05-13 | Diabetic control by combined insulin forms |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE78169T1 true ATE78169T1 (de) | 1992-08-15 |
Family
ID=22502938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT88904864T ATE78169T1 (de) | 1988-01-13 | 1988-05-13 | Behandlung von diabetes durch kombinierte insulinformen. |
Country Status (8)
Country | Link |
---|---|
US (1) | US4863896A (de) |
EP (1) | EP0358709B1 (de) |
AT (1) | ATE78169T1 (de) |
AU (1) | AU622370B2 (de) |
DE (1) | DE3872878T2 (de) |
DK (1) | DK452289A (de) |
FI (1) | FI894376A0 (de) |
WO (1) | WO1989006540A1 (de) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5420108A (en) * | 1992-09-14 | 1995-05-30 | Shohet; Isaac H. | Method of controlling diabetes mellitus |
WO1999016425A1 (en) * | 1997-09-30 | 1999-04-08 | The Ohio State University | Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells |
US7169410B1 (en) * | 1998-05-19 | 2007-01-30 | Sdg, Inc. | Targeted liposomal drug delivery system |
US6159931A (en) * | 1998-09-29 | 2000-12-12 | The Ohio State University | Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells |
US6867183B2 (en) | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US7060675B2 (en) | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7196059B2 (en) | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
AU2003236521A1 (en) * | 2002-06-13 | 2003-12-31 | Nobex Corporation | Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus |
JP5452843B2 (ja) | 2003-01-06 | 2014-03-26 | エミスフィアー テクノロジーズ インコーポレイテッド | 夜間の経口インスリン治療 |
US20050203001A1 (en) | 2004-03-05 | 2005-09-15 | Emisphere Technologies, Inc. | Oral insulin therapies and protocol |
CA2536393A1 (en) * | 2003-09-09 | 2005-06-16 | Gilead Sciences, Inc. | Use of liposomes which are small unilamellar vesicles for the removal of an entity from a biological sample |
CA2580313C (en) * | 2004-07-19 | 2016-03-15 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
CA2609402C (en) * | 2005-05-23 | 2014-10-21 | Sdg, Inc. | Lipid construct for delivery of insulin to a mammal |
US20110135725A1 (en) | 2005-05-23 | 2011-06-09 | Sdg, Inc. | Lipid Construct for Delivery of Insulin to a Mammal |
US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
BRPI0818004B8 (pt) | 2007-10-16 | 2021-05-25 | Biocon Ltd | composição farmacêutica sólida administrável por via oral e o processo da mesma. |
US20120035105A1 (en) * | 2009-01-09 | 2012-02-09 | Sdg, Inc. | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments |
PE20120582A1 (es) | 2009-01-28 | 2012-05-26 | Smartcells Inc | Conjugados de insulina cristalina |
SG173112A1 (en) | 2009-01-28 | 2011-08-29 | Smartcells Inc | Conjugate based systems for controlled drug delivery |
AU2010208381A1 (en) | 2009-01-28 | 2011-08-04 | Smartcells, Inc. | Exogenously triggered controlled release materials and uses thereof |
CA2750252A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Synthetic conjugates and uses thereof |
AU2010226243A1 (en) | 2009-03-20 | 2011-09-22 | Smartcells, Inc. | Terminally-functionalized conjugates and uses thereof |
US8569231B2 (en) | 2009-03-20 | 2013-10-29 | Smartcells, Inc. | Soluble non-depot insulin conjugates and uses thereof |
EP2598170A4 (de) | 2010-07-28 | 2016-07-06 | Smartcells Inc | Arzneimittel-liganden-konjugate, deren synthese und zwischenprodukte daraus |
JP2013541500A (ja) | 2010-07-28 | 2013-11-14 | スマートセルズ・インコーポレイテツド | 組換えレクチン、結合部位修飾レクチンおよびそれらの用途 |
AU2011282988A1 (en) | 2010-07-28 | 2013-01-31 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
BR112016007176A2 (pt) | 2013-10-04 | 2018-01-23 | Merck Sharp & Dohme | conjugado, composição, usos de um conjugado e de uma composição, e, método para tratar um indivíduo que tem diabete |
US11077173B2 (en) | 2017-03-13 | 2021-08-03 | Sdg, Inc. | Lipid-based nanoparticles and methods using same |
KR20190124269A (ko) | 2017-03-13 | 2019-11-04 | 에스디지,인코포레이티드 | 안정성이 증진된 지질 기반 나노입자 |
JP2022526842A (ja) * | 2019-04-12 | 2022-05-26 | エスディージー インコーポレイテッド | 脂質ベースのナノ粒子および最適化されたインスリン投薬レジメンにおけるその使用方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4377567A (en) * | 1978-10-02 | 1983-03-22 | The Procter & Gamble Company | Lipid membrane drug delivery |
US4603044A (en) * | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
-
1988
- 1988-01-13 US US07/143,180 patent/US4863896A/en not_active Expired - Lifetime
- 1988-05-13 AT AT88904864T patent/ATE78169T1/de not_active IP Right Cessation
- 1988-05-13 WO PCT/US1988/001536 patent/WO1989006540A1/en active IP Right Grant
- 1988-05-13 AU AU17905/88A patent/AU622370B2/en not_active Ceased
- 1988-05-13 EP EP88904864A patent/EP0358709B1/de not_active Expired - Lifetime
- 1988-05-13 DE DE8888904864T patent/DE3872878T2/de not_active Expired - Lifetime
-
1989
- 1989-09-13 DK DK452289A patent/DK452289A/da not_active Application Discontinuation
- 1989-09-15 FI FI894376A patent/FI894376A0/fi not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0358709B1 (de) | 1992-07-15 |
FI894376A0 (fi) | 1989-09-15 |
DE3872878T2 (de) | 1992-12-03 |
DK452289A (da) | 1989-11-09 |
WO1989006540A1 (en) | 1989-07-27 |
DE3872878D1 (de) | 1992-08-20 |
EP0358709A4 (de) | 1990-03-08 |
AU622370B2 (en) | 1992-04-02 |
EP0358709A1 (de) | 1990-03-21 |
DK452289D0 (da) | 1989-09-13 |
AU1790588A (en) | 1989-08-11 |
US4863896A (en) | 1989-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE78169T1 (de) | Behandlung von diabetes durch kombinierte insulinformen. | |
Harris | Iontophoresis: clinical research in musculoskeletal inflammatory conditions | |
DK0527835T3 (da) | Doseringsform til afgivelse af et anti-Parkinsonmiddel | |
DK0480934T3 (da) | Lægemiddel, der indeholder ephedrin og koffein til behandling af overvægt | |
ATE232082T1 (de) | Prophylaktische und therapeutische behandlung von haupt sensibilisierung und -reizung | |
GEP20002146B (en) | Therapeutic Peptide Derivatives | |
SE8204874L (sv) | Farmaceutiska preparat, innefattande humant insulin och humant proinsulin | |
KR910005858A (ko) | 지방산 요법 | |
MY105798A (en) | Treatment of leukocyte dysfunction with gm-csf. | |
KR100271087B1 (en) | Protein synthesis stimulator comprising tcf-2 for the treatment of hypoproteinemia | |
AR003979A1 (es) | Administracion transdermica de vorozol. | |
Rosenthal | Alterations in serum thyroxine with cerebral electrotherapy (electrosleep) | |
AR029160A1 (es) | El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo | |
EA199800770A1 (ru) | Лекарственный препарат для терапевтического лечения вирусного гепатита | |
DK1007085T3 (da) | Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet | |
ATE66375T1 (de) | Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung. | |
SE9101341D0 (sv) | New medicinal use | |
JPS6016921A (ja) | 貼付薬 | |
ATE328604T1 (de) | Verwendung von wachstumshormon in niederen dosen | |
GB2019720A (en) | S-adenosyl-L-homocysteine and salts thereof for use in therapy | |
RU94000695A (ru) | Средство с противоаллергическим действием | |
徐济民 et al. | ANTIARRHYTHMIC ACTION OF CHANGROLIN ADMINISTERED BY CONTINUOUS INTRAVENOUS INFUSION | |
RU94020918A (ru) | Способ лечения опсоменореи | |
KR920007624A (ko) | 단백질 의약품의 경구투여용 조성물 | |
UA7412A1 (uk) | Спосіб лікування псоріазу |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |